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Strengths and limitations of this study
 ► The Lengthening Adalimumab Dosing Interval (LADI) 
study is the first randomised controlled trial that 
investigates adalimumab interval lengthening in 
Crohn’s disease patients.
 ► This pragmatic study is clinically relevant and re-
sults can easily be implemented in daily practice.
 ► The National Crohn and colitis patients organisa-
tion is involved and patient- reported outcomes are 
included.
 ► The study is not blinded.
AbStrACt
Introduction Adalimumab is effective for maintenance 
of remission in patients with Crohn’s disease (CD) at a 
dose of 40 mg subcutaneously every 2 weeks. However, 
adalimumab is associated with (long- term) adverse events 
and is costly. The aim of this study is to demonstrate non- 
inferiority and cost- effectiveness of disease activity guided 
adalimumab interval lengthening compared to standard 
dosing of every other week (EOW).
Methods and analysis The Lengthening Adalimumab 
Dosing Interval (LADI) study is a pragmatic, multicentre, 
open label, randomised controlled non- inferiority trial. 
Non- inferiority is reached if the difference in cumulative 
incidence of persistent (>8 weeks) flares does not 
exceed the non- inferiority margin of 15%. 174 CD 
patients on adalimumab maintenance therapy in long- 
term (>9 months) clinical and biochemical remission 
will be included (C- reactive protein (CRP) <10 mg/L, 
faecal calprotectin (FC) <150 µg/g, Harvey- Bradshaw 
Index (HBI) <5). Patients will be randomised 2:1 into the 
intervention (adalimumab interval lengthening) or control 
group (adalimumab EOW). The intervention group will 
lengthen the adalimumab administration interval to every 
3 weeks, and after 24 weeks to every 4 weeks. Clinical 
and biochemical disease activity will be monitored every 
12 weeks by physician global assessment, HBI, CRP and 
FC. In case of disease flare, dosing will be increased. A 
flare is defined as two of three of the following criteria; 
FC>250 µg/g, CRP≥10 mg/l, HBI≥5. Secondary outcomes 
include cumulative incidence of transient flares, adverse 
events, predictors for successful dose reduction and cost- 
effectiveness.
Ethics and dissemination The study is approved by 
the Medical Ethics Committee Arnhem- Nijmegen, the 
Netherlands (registration number NL58948.091.16). 
Results will be published in peer- reviewed journals and 
presented at international conferences.
trial registration numbers EudraCT registry (2016-
003321-42);  Clinicaltrials. gov registry (NCT03172377); 
Dutch trial registry (NTRID6417).
bACkground
Crohn’s disease (CD) is a chronic inflam-
matory disease of the gastrointestinal tract, 
characterised by a relapsing and remitting 
disease course. Patients show an abnormal 
mucosal immune response, resulting from 
an interplay of genetic susceptibility, environ-
mental factors and the intestinal microflora.1 
Treatment consists of immunosuppressive 
medication, including monoclonal anti-
bodies that block tumour necrosis factor 
alpha (anti- TNF); such as infliximab, adali-
mumab and certolizumab. Adalimumab is a 
humanised anti- TNF antibody that is effective 
as both induction and maintenance therapy 
for CD.2–4 Adalimumab is administered by 
subcutaneous (sc) injection and an induction 
dose of 80 mg (week 0) and 40 mg (week 2) 
or 160 mg (week 0) and 80 mg (week 2) are 
generally used, followed by 40 mg every 2 
weeks.5
Although adalimumab is generally safe, side 
effects do occur. The risk of (opportunistic) 
infections is increased, especially in combi-
nation with immunosuppressive therapies, 
most often thiopurines or methotrexate.6–9 
A recently published review on long term 
safety of adalimumab (n=3606 CD patients) 
showed a high absolute risk of any infection 
of 119 events per 100 patient years (PYs) 
and a risk of serious infection of 6.7/100 
PYs in this selected trial- population with 
relatively low comorbidity.10 The incidence 
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rate of injection site reactions (local pain and swelling) 
was 7.7/100 PYs.10 In addition, several reports show an 
increased risk of skin cancer (both melanoma and non- 
melanoma skin cancer), especially in combination with 
thiopurines.6 7 9 11 12 In addition to potential side effects, 
the costs of adalimumab are significant. Before the intro-
duction of biosimilars, the costs of anti- TNF in the Neth-
erlands were €15 000–30 000 per CD patient annually.13 14 
Anti- TNF including adalimumab is expected to continue 
to be the main cost driver of CD management for several 
reasons. First, the number of CD patients is increasing in 
the Netherlands.15 Second, recent data stimulate an early 
use of anti- TNF with an accelerated step- up or top- down 
approach in combination with treat- to- target (mucosal 
healing), to prevent bowel damage.16 Third, the entry 
of lower cost biosimilars will possibly cause physicians to 
preferentially prescribe anti- TNF treatment, which will 
increase its use.17–19
Discontinuation of adalimumab therapy in CD patients 
in stable clinical remission is a clinical strategy that may 
aid in reducing the risk of side effects, costs and avoid 
prolonged immunosuppression during a quiescent 
disease course. However, in a large meta- analysis on indi-
vidual patient data (n=1330, including the landmark 
study by Louis et al20) on cessation of anti- TNF therapy, 
approximately 38% of the patients had a relapse in 1 year, 
and 52% after 2 years of follow- up (Pauwels et al, unpub-
lished data). Therefore, an alternative strategy of dose 
reduction of adalimumab rather than discontinuation 
may be considered. In rheumatoid arthritis (RA), the 
Dose REduction Strategy of Subcutaneous TNF inhibi-
tors (DRESS) study concluded that disease activity guided 
dose reduction of anti- TNF is non- inferior and cost- 
effective, compared with maintaining regular dosing.21 22 
However, extrapolation of these results to CD is question-
able, since RA patients generally use different concom-
itant medication, suffer from different comorbidities 
and anti- TNF shows different pharmacodynamic char-
acteristics in RA patients.23 24 In CD, adalimumab dose 
reduction is uncommon in daily practice. Only two retro-
spective cohort studies (n=46+40) reported CD patients 
who used adalimumab 40 mg every 3 weeks (ETW).25 26 
After a median follow- up of 16 and 24 months, respec-
tively 63% and 65% remained in clinical remission.
The aim of this randomised controlled trial is to demon-
strate non- inferiority and cost- effectiveness of disease 
activity guided adalimumab injection interval length-
ening compared with standard of care (continued every 
other week (EOW) dosing) in maintaining remission in 
CD. In this paper we describe the study design as well as 
potential pitfalls and outcomes.
objECtIvE
Primary objective
 ► To demonstrate non- inferiority of disease activity 
guided adalimumab injection interval lengthening 
compared with adalimumab EOW dosing (standard 
of care) in CD patients in stable disease remission at 
48 weeks of follow- up. Non- inferiority is reached if 
the difference in cumulative incidence of persistent 
flares not exceeds the non- inferiority margin of 15%. 
A persistent flare is defined as two of three of the 
following criteria, persisting for >8 weeks despite dose 
escalation of adalimumab:
 – Faecal calprotectin (FC) >250 µg/g.
 – C- reactive protein (CRP) ≥10 mg/L.
 – Harvey- Bradshaw Index (HBI) ≥5.
Secondary objectives
 ► To report the proportion of patients that had successful 
interval lengthening, defined as the absence of a 
disease flare, while treated with adalimumab ETW or 
every 4 weeks (EFW), at week 48.
 ► To identify factors that are associated with successful 
interval lengthening (eg, baseline patient and treat-
ment characteristics, FC, CRP, adalimumab drug 
levels and antibodies to adalimumab).
 ► To compare the cumulative incidence of patients with 
a transient flare (duration ≤8 weeks) between the 
intervention and control group at week 48.
 ► To compare the proportion of patients that used 
budesonide, prednisone or other immunomodulators 
in order to treat a (transient) flare.
 ► To compare the proportion of patients in clinical 
and biochemical remission between the intervention 
and control group at week 48. Remission is defined 
as an HBI <5, FC <150 µg/g and CRP <10 mg/L. In 
case disease activity is assessed with endoscopy or MRI 
scan, that conclusion overrules our definition.
 ► To compare inflammatory bowel disease (IBD)- 
specific quality of life by the Short- IBD Questionnaire 
(SIBDQ)) between the intervention and control 
group every 12 weeks during follow- up.
 ► To compare disease activity by HBI and patient 
reported outcome (PRO-2) between the inter-
vention and control group every 12 weeks during 
follow- up.
 ► To compare medical consumption (by institute for 
Medical Technology Assessment (iMTA) Medical 
Consumption Questionnaire (MCQ)) and work 
productivity (by iMTA Productivity Cost Question-
naire (PCQ)) between the intervention and control 
group until week 48, in order to calculate the decre-
mental cost- effectiveness ratio of this interval length-
ening strategy.
 ► To compare the rates of (serious) adverse events ((S)
AEs) that are (possibly) related to adalimumab and 
the rates of (S)AEs that are (possibly) related to adal-
imumab interval lengthening between the interven-
tion and control group, expressed as events/100 PYs 
of follow- up.
 ► To compare adalimumab use between the interven-
tion and control group, including the cumulative 
dose during follow- up, the proportion of patients that 
uses adalimumab ETW and EFW.
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MEthodS
This protocol includes the standard protocol items 
recommended for interventional trials according to the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (online supplemen-
tary file 1).27
design
This randomised controlled trial is currently being 
performed at the departments of Gastroenterology and 
Hepatology in 21 hospitals in the Netherlands, including 
both academic and non- academic centres. The aim of the 
adalimumab interval lengthening strategy is to minimise 
the amount of adalimumab use while maintaining remis-
sion in CD. Therefore, longer adalimumab intervals will 
be compared with adalimumab EOW in a non- inferiority 
design (to show the same effect is maintained with a dose 
reduction strategy), instead of a superiority design, which 
is used to demonstrate that an intervention leads to supe-
rior outcomes than the standard of care. The rationale 
behind a non- inferiority design is that benefits may be 
present in other areas (ie, fewer side effects, lower costs) 
so that the intervention would be preferred if its efficacy 
is not worse.
The date of the first enrolment was 3 May 2017. The 
study is approved by the Medical Ethical Committee 
(METC) Arnhem- Nijmegen (registration number 
NL58948.091.16). Important protocol modifications 
are assessed and approved by the METC, and reported 
to participating investigators. The most recent study 
protocol version 3.3 (July 2018) is presented in this manu-
script. The Lengthening Adalimumab Dosing Interval 
(LADI) study has been registered at  clinicaltrials. gov and 
the Dutch trial registry. A data safety monitoring board is 
installed in order to independently assess the efficacy and 
safety of the study intervention and to monitor the overall 
conduct of the trial. Prior to enrolment, all patients have 
to sign informed consent (online supplementary file 2).
Patient and public involvement
The study was designed in collaboration with the Dutch 
Crohn’s and colitis patient organisation (CCUVN) in 
order to optimise patient participation. We based our 
study design on the results of a biological focus group by 
members of the CCUVN. This focus group showed that 
patients do accept a reduction of the dose of their biolog-
ical agent. Additionally, based on previous interactions 
with the CCUVN, we have included patient focused 
outcomes in our study, such as the quality of life and 
PRO-2.
Inclusion and exclusion criteria
All adult CD patients with colonic and/or distal ileal 
and/or proximal CD, who are treated with adalimumab 
40 mg every 2 weeks at a stable dose, at least 9 months 
in steroid- free clinical remission and not scheduled 
for CD- related surgery, are eligible for participation.28 
Remission is defined as an HBI <5, FC <150 µg/g and 
CRP <10 mg/L. The current guidelines from the Euro-
pean Crohn’s and Colitis Organisation (ECCO) suggest 
to use CRP <10 mg/L for the definition of disease remis-
sion.5 Endoscopic assessment prior to enrolment is not 
mandatory, however if an ileocolonoscopy was performed 
before the start of the study and demonstrated complete 
mucosal healing (Simple Endoscopic Score- CD <3 or no 
ulcerations), an FC <250 µg/g is accepted as inclusion 
criterium. Permitted concomitant CD therapies are: 
aminosalicylates, azathioprine, 6- mercatopurine, meth-
otrexate and thioguanine at a stable dose for 12 weeks. 
Patients with arthralgia will be included, however inflam-
matory arthritis is an exclusion criterium, as this can 
provide elevated inflammatory markers. Furthermore, 
patients with active draining fistulas are excluded. Other 
exclusion criteria are pregnancy or lactation and other 
significant medical conditions that might interfere with 
this study (such as a current/recent malignancy, immu-
nodeficiency syndromes and psychiatric illness), or when 
it is to be expected that the outcome cannot be measured 
(short life expectancy, planned major surgery, language 
issues).
Study groups
Control group
The control group continues maintenance treatment 
with adalimumab sc 40 mg EOW. Treatment decisions are 
made at the discretion of the treating physician. Of note, 
dose reduction beyond 40 mg per 2 weeks is currently 
not recommended according to national guidelines.29 
Patients follow a standardised protocol based on the tight 
control/treat- to- target principle in order to maintain low 
disease activity.16
Intervention group
Adalimumab interval will be lengthened through a step-
wise disease activity guided manner.
Step 1: On inclusion, the interval will be prolonged to 
ETW.
Step 2: After week 24, patients in remission will lengthen 
their dosing interval to EFW.
Step 3: If adalimumab interval lengthening leads to 
a confirmed flare, patients will return to the preceding 
effective interval (figure 1). If a flare is not objectively 
confirmed, patients are advised to continue adalim-
umab in their study- interval. However, interval reduction 
is accepted if patients really want this as this situation 
reflects daily clinical practice.
In contrast to the DRESS study, the discontinuation of 
therapy after successful de- escalation to 40 mg EFW is not 
implemented in the study protocol.21 Total follow- up time 
will be 48 weeks. Follow- up visits and outcome measure-
ments are similar to the control group.
Cointervention
The use of previously mentioned concomitant medica-
tion is allowed and must be documented on the case- 
report form (CRF) (stating type, dosage and duration). If 
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Figure 1 Protocolised treatment recommendation in case of disease flare. T0: start of possible disease flare, which can occur 
at any time during follow- up, T2: 2 weeks after T0, T6−8: 6–8 weeks after T0. Lab tests include haemoglobin, leucocytes, 
thrombocytes, albumin, C- reactive protein, calprotectin.
possible, existing concomitant medication should not be 
changed during the study.
If patients experience worsening of symptoms in 
between visits, they must contact the outpatient clinic. 
For further treatment of the flare, patients in the control 
arm are referred to their treating physician. In the inter-
vention arm, patients will return to the preceding effec-
tive adalimumab dosing interval (figure 1). The decision 
to start concomitant therapy remains at the discretion of 
the treating physician.
Secondary outcome measurements
Quality of life
For assessment of quality of life, we will use the SIBDQ, 
which is a validated and disease- specific questionnaire.30
Patient reported disease activity
We will use the only validated IBD patient- reported 
outcome measure, ‘PRO-2’, consisting of reported diar-
rhoea and abdominal pain.31
Factors associated with successful dose reduction
Factors which are possibly related to successful dose 
reduction include: baseline patient and treatment char-
acteristics, adalimumab drug levels (µg/mL) and anti-
bodies (AU/mL), clinical (physician global assessment, 
HBI) and laboratory results (FC (µg/g), CRP (mg/L), 
haemoglobin (g/L), leucocytes (109/L), platelets 
(109/L), albumin (g/L)).
Safety
AEs and SAEs are registered during follow- up. All SAEs 
are reported to the METC Arnhem- Nijmegen.
Cost-effectiveness
The impact of dose reduction on the quality of life of 
patients will be assessed by the EuroQuol- 5D (EQ- 5D) 
at 24 and 48 weeks following randomisation, compared 
with baseline. The EQ- 5D utility will be used to derive 
a quality- adjusted life year (QALY) estimate for each 
patient according to the trapezium rule.32 33
Assessments
Enrolled patients will visit the outpatient clinic every 
24 weeks. If preferred by the patient or treating physi-
cian, the evaluations at week 12 and 36 can take place 
as outpatient clinic visit as well. Every 12 weeks, labora-
tory tests (eg, FC, CRP, haemoglobin and albumin) will 
be performed. At week 0, 24 and 48 serum samples are 
stored for measurement of adalimumab drug levels and 
antibodies to adalimumab. Additionally, patients in both 
arms will be interviewed via telephone every 6 weeks in 
between clinical visits to assess for adverse events, symp-
toms and potential disease activity. If such an interview 
suggests a disease flare, patients must visit the outpatient 
clinic in order to undergo complete disease activity assess-
ment and laboratory and FC tests. If patients have a flare 
at week 48, disease activity will be monitored until disease 
remission, in order to define the flare as persistent- or 
transient flare. In addition, study questionnaires are auto-
matically sent via Castor every 12 weeks. During follow- up, 
patients register the adalimumab injection dates in a 
study- diary and bring this to the outpatient clinic every 
visit to evaluate adherence to adalimumab. An overview 
of all visits and assessments is depicted in table 1 and 
figures 1 and 2.
randomisation, allocation concealment, stratification
Patients are randomised by the research physician using 
a computer- generated randomisation system (Castor). 
Castor uses a validated variable block randomisation 
model with block sizes of 6, 9 and 12. Patients will be 
randomised in a 2:1 ratio for the intervention or the 
control group, respectively. We chose 2:1 randomisation 
to stimulate patient inclusion, as patients have a higher 
chance to randomise for the intervention group. Further-
more, more determinants can be included in a prediction 
model for successful dose reduction if the intervention 
group is larger. Patients will be stratified on comedi-
cation use (yes/no), as the incidence of flares could 
possibly be different with or without comedication use. 
Comedication includes azathioprine, 6- mercaptopurine, 
6- thioguanine, methotrexate. Both patients and physi-
cians are un blinded, as we aim to represent daily practice 
during this pragmatic study.
Sample size
The null hypothesis in non- inferiority studies is that the 
intervention is inferior compared with the control arm 
by more than the non- inferiority margin. The alterna-
tive hypothesis is that the intervention is not worse than 
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Table 1 SPIRIT schedule of enrolment, interventions and assessments
Study period
Enrolment Allocation Follow- up Extra
Timepoint −t1 0 w0 w6 w12 w18 w24 w30 w36 w42 w48 we
Enrolment
  Eligibility screen X
  Informed consent X
  Allocation X
Interventions
  Intervention: lengthening 
adalimumab dosing interval
  
  Control: adalimumab every 
other week
  
Assessments
  Medical history X X
  Laboratory tests* X X X X X X
  Faecal calprotectin X X X X X X
  Storage of serum samples X X X X
  Concomitant medication X X X X X X X X X X
  (Serious) adverse events X X X X X X X X X X
  Physician global assessment X X X X X X X X X X
  HBI X X X X X X
  PRO-2, IBD- Q and EQ5D X X X X X
  iMTA MCQ, PCQ X X X X X
*Haemoglobin, leucocytes, thrombocytes, albumin, C- reactive protein.
EQ- 5D, EuroQuol- 5D; HBI, Harvey Bradshaw Index; IBD- Q, Inflammatory Bowel Disease Questionnaire; iMTA MCQ, institute for Medical 
Technology Assessment Medical Consumption Questionnaire; PCQ, Productivity Cost Questionnaire; PRO-2, patient reported outcome-2; 
SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials.
Figure 2 Schematic presentation of the trial design. ADA, adalimumab; W0, week 0; W6, week 6 and so on. Lab tests include 
haemoglobin, leucocytes, thrombocytes, albumin, C- reactive protein, calprotectin.
the control by more than the non- inferiority margin. 
Therefore, if the null hypothesis is rejected, the alter-
native hypothesis that the intervention is non- inferior is 
accepted.34 Based on an extrapolation of data from the 
DRESS study and results from a real- life CD cohort in 
Leuven, an estimated 15% of patients will experience 
the primary outcome (persistent flare) in the control 
arm. In the Leuven cohort, 41/156 (26%) patients 
discontinued adalimumab due to loss of response, 
despite adalimumab dose escalation.21 35 The latter 
26% was adjusted to an expected 15% for our cohort 
because the follow- up time in our cohort concerns 12 
rather than 20 months, and our cohort is a preselected 
cohort of patients in long and stable remission rather 
than a cross- sectional cohort. In non- inferiority analyses, 
one- sided testing is used. Applying one sided testing, an 
alpha of 0.05 (Zα=1.64), power 1- beta 0.8 (Zβ=0.84), a 
non- inferiority margin of 15% and randomisation ratio 
of 2:1 intervention versus control resulted in n=105 and 
n=53 for intervention and control arm, respectively. 
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Accounting for a 10% drop- out, 174 patients have to be 
included in total.
A non- inferiority margin of 15% means a maximum 
difference in persistent flare of 15% between the usual 
care and intervention group. We believe this strikes an 
acceptable balance between the potential harms of flare, 
and the benefits of dose reduction (fewer injections, 
potential for reduced risk of side effects and cost- savings). 
The large Nor- Switch trial also used a non- inferiority 
margin of 15% for disease worsening during follow- up.36 
Based on this example, discussions in our study- group 
and approval of the protocol by the Dutch Organisation 
for Health Research and Development, we believe this 
margin is appropriate. The DRESS study used a non- 
inferiority margin of 20%. Although side effects/SAEs of 
adalimumab seem comparable in RA versus IBD, rheu-
matologists probably accept a higher proportion of flares 
because there are more alternative biological therapies 
available, thus a loss of effect of one biological therapy 
might be given less weight in RA.6
Planned data analysis
The primary outcome; cumulative incidence of persistent 
flares will be expressed as proportions in both groups. A 
CI for the difference between study groups will be deter-
mined (adjusted for comedication use at baseline using 
the Cochran- Mantel- Haenszel procedure, as this variable 
is used for stratification in the randomisation process).37 
The upper limit of the CI will be compared with the non- 
inferiority margin. We will use both intention to treat and 
per protocol analyses, as the latter is considered the most 
conservative analysis for non- inferiority trials.38 Patients 
in the interval lengthening group are included in the per 
protocol analyses if they: lengthened the adalimumab 
interval at least to 3 weeks, regardless whether they returned 
to a preceding effective interval in case of a disease flare. 
Patients in the control group are included in the per 
protocol analyses if they: used adalimumab EOW without 
consistent interval lengthening, incidental postpone-
ment of an injection during infection or around holidays 
is allowed. Descriptive patient (and treatment) baseline 
variables will be summarised as means±SD, medians with 
IQRs or percentages, depending on the type of measure-
ment. Gender, body mass index, age, prior medication for 
CD, disease duration, Montreal classification, IBD- related 
surgical history, comorbidity, inflammatory parameters 
including HBI, FC, CRP, adalimumab drug levels and anti-
bodies to adalimumab will be reported.
The secondary continuous outcomes HBI, SIBDQ, 
PRO-2, adalimumab drug levels and antibody levels at 48 
weeks will be analysed by either Student’s t- test or Mann- 
Whitney U test depending on the type of distribution of the 
data. In addition, the course over time for several contin-
uous outcomes measured at multiple time points (every 12 
weeks) will be analysed using repeated measures analyses 
in which the outcome can be corrected for the baseline 
value of the specific outcome and potential confounding 
factors. The number of (S)AEs that are (possibly) related 
to adalimumab or to adalimumab interval lengthening will 
be reported as rates, defined as events/100 PYs of follow- up; 
details of these (S)AEs will be provided. In the intervention 
group, patient characteristics and clinical features will be 
analysed to predict a persistent flare. A prediction model 
will be developed and fitted using a univariable selection 
based on a p value <0.2 and a multivariable approach with 
backward selection. Predictive accuracy will be determined 
by the area under the receiver operating curve. A two- 
sided p value of <0.05 is considered statistically significant. 
All statistical analyses will be performed by using IBM SPS 
Statistics V.25.0.
Cost-effectiveness analysis
The cost analysis consists of two main parts. First, at patient 
level, volumes of care related to the CD care and anti- TNF 
therapy will be measured by means of the iMTA MCQ. This 
questionnaire measures all relevant healthcare related 
costs like outpatient visits at any medical specialist, hospi-
talisations and imaging procedures. Loss of productivity 
due to illness or recovery in patients below the age of 65 
years will be estimated based on patient reported absences 
from paid (or unpaid) labour measured with the PCQ. The 
second part of the cost analysis consists of determining the 
cost prices for each volume of consumption. The standard 
cost prices from the ‘Dutch Guidelines for Cost Analyses’ 
and www. medicijnkosten. nl will be used. For units of care 
where no standard prices are available real costs prices will 
be determined on the basis of full cost pricing. Productivity 
losses will be valued by means of the friction cost method. 
In the end volumes of care will be multiplied with the cost 
prices for each volume of care to calculate costs. Because 
we anticipate non- inferiority of the dose reduction strategy, 
we will primarily analyse cost- savings: direct medical cost 
as well as total costs (medical and non- medical costs) will 
be compared between intervention and control group. A 
possible small but acceptable loss of effect can be incor-
porated in the analyses by determining a decremental 
cost- effectiveness ratio (DCER) by dividing the difference 
in costs by the difference in QALYs between the groups. 
The DCER expresses with how much money a loss of one 
QALY is compensated. If this amount is high the decision 
makers may be willing to accept a loss of effect. Uncertainty 
in the DCER will be non- parametrically determined using 
bootstrap techniques (1000 replications). Results from this 
analysis will be presented in a scatter plot and willingness 
to pay (or accept) curve. Furthermore, the Net Monetary 
Benefit per patient will be calculated for different levels 
of willingness to accept (WTA) in euro’s per QALY, using 
the formula: WTA×effect (difference in QALY)−costs. This 
results in the net amount of money saved, when the possible 
loss of QALY is corrected for, using different WTA levels per 
QALY.
Ethics and dissemination
The study is approved by the Medical Ethics Committee 
Arnhem- Nijmegen, the Netherlands (registration number 
NL58948.091.16). Data of all participating centres will be 
Protected by copyright.
 o
n
 June 8, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035326 on 26 May 2020. Downloaded from 
7Smits LJT, et al. BMJ Open 2020;10:e035326. doi:10.1136/bmjopen-2019-035326
Open access
collected by electronic CRFs and monitored following 
good clinical practice (GCP) guidelines. The collected 
data will be entered in Castor, an electronic database set 
up for clinical trials (https://www. castoredc. com). Data 
will be coded and kept based on the rules for GCP by certi-
fied personnel. Results will be published in peer- reviewed 
journals and presented at international conferences.
dISCuSSIon
Dose reduction of adalimumab in CD patients with stable 
disease may provide similar disease control but reduction 
of adverse events and costs. With this pragmatic, non- 
inferiority study design we aim to evaluate the outcomes 
of this strategy. Only two small retrospective studies 
reported on adalimumab 40 mg ETW in CD patients, and 
demonstrated that approximately two thirds of patients 
could safely de- escalate adalimumab.25 26 However, no 
prospective randomised data are available to confirm 
these data. Prior studies have investigated the effect of 
discontinuation of anti- TNF therapy in CD.20 39–41 Previous 
clinical trials on withdrawal of anti- TNF after a period of 
prolonged remission in CD patients showed a relatively 
consistent profile of 42% relapses after anti- TNF cessa-
tion within 1 year of follow- up.39–41 Louis et al identified 
risk factors for disease flare after discontinuation of inflix-
imab in CD patients who used infliximab and thiopurine 
combination therapy for at least 1 year. Risk factors for 
relapse included male sex, high leucocyte counts, high 
CRP, high FC and low levels of haemoglobin.20 The multi-
centre randomised CEASE trial (Diagnostic tool to safely 
CEASE anti- TNF therapy in Crohn's disease,ZonMw 
project number 848101009) will further investigate 
cessation of anti- TNF. As cessation of anti- TNF therapy 
is a different research question with different outcome 
measures, uncertainty remains on factors that are asso-
ciated with successful adalimumab interval lengthening 
and the LADI study will provide useful information for 
daily clinical practice.
We decided to assess non- inferiority with regard to 
persistent flares (persisting >8 weeks independent of 
treatment changes such as adalimumab dose escalation) 
since these are the most relevant clinical outcomes in 
this setting. Temporary flares (persisting <8 weeks) that 
resolve after appropriate treatment are less difficult to 
manage and are likely to occur as an acceptable result 
of searching for the optimal individualised treatment 
interval. Temporary flares will still function as relevant 
secondary outcome in our trial. For the definition of a 
flare, two consecutive measurements demonstrating two 
out of three of the following criteria; FC >250 µg/g, CRP 
≥10 mg/L, HBI ≥5 are required. As it has been shown 
that flares are frequently temporary and occur and some-
times disappear without regimen change, a flare is only 
considered a flare if it is confirmed two times. For this 
composite endpoint we preferred to incorporate the HBI 
instead of the Crohn’s Disease Activity Index on account 
of accessible clinical implementation in daily practice. 
In addition, FC and CRP are non- invasive, cheap and 
widely available biomarkers of disease activity.42 Further-
more, FC correlates to endoscopic disease activity.43 44 
Recently, it was shown that an increase in FC can precede 
on the onset of clinical symptoms.45 Indeed, due to our 
definition of a flare, patients without clinical symptoms 
can also fulfil the definition of a (biochemical) flare. 
In addition, the requirement of an elevation in inflam-
matory markers at two time points allows for the exclu-
sion of confounders such as Clostridium difficile infection 
and use of ‘non- steroidal anti- inflammatory drugs’ 
(NSAIDs).
We decided not to include endoscopy outcomes in the 
inclusion criteria or primary endpoint. An endoscopic 
procedure is a burden for patients due to the invasive 
procedure and the intensive preparation. In addition, we 
aimed for study results that may be easily implemented in 
daily practice. Instead of an endoscopy, we used a combi-
nation of surrogate markers of inflammation including 
HBI, CRP and FC to determine clinical remission. A 
protocolised treatment is advised when a flare occurs 
(figure 1). However, treatment choices are not manda-
tory and bridging therapy (including steroids) is left to 
the discretion of the treating physician.
For the study design, a blinded design was considered, 
but the development, costs and administration of placebo 
injections would create a formidable barrier for the study. 
Furthermore, an un- blinded (pragmatic) design fits best 
with the current ideas about the external validity of cost- 
effectiveness studies. This design mirrors the real- life 
setting which is also not blinded, with respect to costs and 
effects. In general, an unblinded study design could result 
in information and attribution bias, for example, flares in 
patients in whom the dose is reduced would possible be 
reported sooner. Because this will not lead to an under-
estimation of the drawbacks of a dose reduction strategy, 
this bias was accepted.
Our trial will provide important insights in addition 
to the risk of recurrence as well as the risk of persistent 
flares. For example, we will collect valuable series of drug 
measurements of adalimumab. Although the DRESS 
study did not show predictive value of drug levels for the 
success of dose reduction, daily IBD practice does apply 
measurement of drug levels. It is possible that drug levels 
at baseline, either low or high, may predict successful 
dose reduction.
From a societal perspective, it is important to improve 
the cost- effectiveness of IBD healthcare. Patients with 
chronic inflammatory diseases use expensive medication 
for many years and there is a growing amount of new 
(expensive) drugs that will soon be implemented in daily 
clinical care. In RA and psoriasis, dose reduction trials in 
adalimumab treated patients are performed and in RA 
the feasibility of this strategy was already demonstrated 
and results from a Dutch nation- wide psoriasis trial will 
follow soon.21 46 The recent introduction of biosimilars 
of adalimumab will further aid in cost reduction but 
the new costs of this therapy will still remain significant. 
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Therefore, cost savings due to dose reduction will remain 
relevant.
In conclusion, we designed a pragmatic randomised 
controlled trial to assess the non- inferiority of a strategy 
of adalimumab dose reduction in CD patients. Accurate 
prediction of successful tapering may aid in reduction of 
adverse events and costs to further improve care for CD 
patients.
Acknowledgements This study is supported by the Dutch Initiative on Crohn 
and Colitis (ICC), a nationwide network of IBD centres that aims at initiating and 
facilitating IBD research. We thank Dr A A den Broeder, rheumatologist at St. 
Maartenskliniek Nijmegen, for his invaluable help in designing the study.
Collaborators Centres and lead investigators that collaborate as "LADI study 
group": Albert Schweitzer Hospital, Dordrecht, The Netherlands; F.H.J. Wolfhagen, 
MD PhD, Department of Gastroenterology. Amphia Hospital, Breda, The Netherlands; 
A.G.L. Bodelier, MD PhD, Department of Gastroenterology. Amsterdam University 
Medical Centre- location AMC, Amsterdam, The Netherlands; M. Löwenberg, MD 
PhD, Department of Gastroenterology. Amsterdam University Medical Centre- 
location VUmc, Amsterdam, The Netherlands; N. de Boer, MD PhD, Department of 
Gastroenterology. Bernhoven Hospital, Uden, The Netherlands; I.A.M. Gisbertz, MD 
PhD, Department of Gastroenterology. Canisius- Wilhelmina Hospital, Nijmegen, 
The Netherlands; A.C.I.T.L. Tan, MD PhD, Department of Gastroenterology. 
Erasmus Medical Centre, Rotterdam, The Netherlands; C.J. van der Woude, MD 
PhD, Department of Gastroenterology. Elisabeth- Tweesteden Hospital, Tilburg, 
The Netherlands; M.W.M.D. Lutgens, MD PhD, Department of Gastroenterology. 
Flevoziekenhuis Hospital, Almere, The Netherlands; R.C. Mallant- Hent, MD PhD, 
Department of Gastroenterology. Franciscus Gasthuis & Vlietland, Rotterdam, 
The Netherlands; R.L. West, MD PhD, Department of Gastroenterology. Ikazia 
Hospital, Rotterdam, The Netherlands; P.C.J. ter Borg, MD PhD, Department of 
Gastroenterology. Jeroen Bosch Hospital, Den Bosch, The Netherlands; T.E.H. 
Römkens, MD PhD, Department of Gastroenterology. Leiden University Medical 
Centre, Leiden, The Netherlands; A.E. van der Meulen, MD PhD, Department 
of Gastroenterology. Maastricht University Medical Centre+, Maastricht, The 
Netherlands; M. Pierik, MD PhD, Department of Gastroenterology. Maxima 
Medical Centre, Veldhoven/Eindhoven, The Netherlands; P.J. Boekema, MD PhD, 
M.L. Verhulst, MD PhD, Department of Gastroenterology. Medisch Spectrum 
Twente, Enschede, The Netherlands; M.G.V.M. Russel, MD PhD, Department of 
Gastroenterology. Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands; 
J. Jansen, MD PhD, Department of Gastroenterology. Radboud University 
Medical Centre, Nijmegen, The Netherlands; F. Hoentjen, MD PhD, Department of 
Gastroenterology. Reinier de Graaf Hospital, Delft, The Netherlands; S.V. Jansen, MD, 
Department of Gastroenterology. University Medical Centre Utrecht, Utrecht, The 
Netherlands; B. Oldenburg, MD PhD, Department of Gastroenterology. Zuyderland 
Hospital, Heerlen/Sittard, The Netherlands; M.J.L. Romberg- Camps, MD PhD, A.A. 
van Bodegraven, MD PhD, Department of Gastroenterology. Data safety monitoring 
board: R.J.M Brüggemann, PharmD PhD, Department of Pharmacy, Radboud 
University Medical Centre, Nijmegen, The Netherlands (chair). J. in t Hout, PhD, 
Department for Health Evidence, Radboud University Medical Centre, Nijmegen, 
The Netherlands. R.J. de Knegt, MD PhD, Department of Gastroenterology and 
Hepatology, Erasmus Medical Centre, Rotterdam, The Netherlands. Independent 
expert: E.T.T.L. Tjwa, MD PhD, Department of Gastroenterology and Hepatology, 
Radboud University Medical Centre, Nijmegen, The Netherlands.
Contributors FH and CJvdW designed the LADI study. WK provided statistical 
expertise in clinical trial design. ACdV, DJdJ, RWMP, LJTS critically reviewed the 
study design. Study coordinators LJTS and RWMP ensure daily study management. 
LJTS and RWMP drafted the manuscript and all authors read, revised and approved 
the final manuscript. Principal investigators: FH, MD PhD and CJvdW, MD PhD. LJTS 
and RWMP share first authorship. FH and CJvdW share last authorship.
Funding The investigator initiated LADI study is supported by the Netherlands 
Organisation for Health Research and Development (ZonMw, Healthcare Efficiency 
programme, grant number 848015002). ZonMw is part of the Netherlands 
Organisation for Scientific Research (NWO). Sponsor: Radboud University Medical 
Centre P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Competing interests DJdJ received consulting fees from Synthon Pharma, 
Abbvie and MSD, and travel fees from Falk Pharma, Takeda, Abbvie, MSD, Ferring, 
Vifor Pharma and Cablon Medical. ACDV has participated in advisory board and/
or received financial compensation from the following companies: Jansen, Takeda, 
Abbvie and Tramedico. FH has served on advisory boards or as speaker for Abbvie, 
Janssen- Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk, and received 
unrestricted funding from Dr Falk, Janssen- Cilag, Abbvie and Celgene. CJvdW 
received grant support from Falk Benelux and Pfizer; received speaker fees from 
AbbVie, Takeda, Ferring, Dr Falk Pharma, Hospira, Pfizer; and served as a consultant 
for AbbVie, MSD, Takeda, Celgene, Mundipharma and Janssen.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to 
the Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement The dataset generated during the LADI study is 
available on reasonable request.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
Author note Coordinating centers are: Radboud University Medical Centre, 
Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands. 
Erasmus Medical Centre, Department of Gastroenterology and Hepatology, 
Rotterdam, The Netherlands.
orCId ids
L J T Smits http:// orcid. org/ 0000- 0002- 4090- 0738
R W M Pauwels http:// orcid. org/ 0000- 0002- 2118- 5687
rEFErEnCES
 1 Torres J, Mehandru S, Colombel J- F, et al. Crohn's disease. Lancet 
2017;389:1741–55.
 2 Colombel J- F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for 
maintenance of clinical response and remission in patients with 
Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52–65.
 3 Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for 
maintenance treatment of Crohn's disease: results of the classic II 
trial. Gut 2007;56:1232–9.
 4 Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti- tumor 
necrosis factor monoclonal antibody (adalimumab) in Crohn's 
disease: the CLASSIC- I trial. Gastroenterology 2006;130:323–33.
 5 Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence- 
based Consensus on the Diagnosis and Management of Crohn’s 
Disease 2016: Part 1: Diagnosis and Medical Management. ECCOJC 
2017;11:3–25.
 6 Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long- 
term safety in 23 458 patients from global clinical trials in rheumatoid 
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, 
psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 
2013;72:517–24.
 7 Osterman MT, Sandborn WJ, Colombel J- F, et al. Increased risk 
of malignancy with adalimumab combination therapy, compared 
with monotherapy, for Crohn's disease. Gastroenterology 
2014;146:941–9.
 8 Pariente B, Laharie D. Review article: why, when and how to de- 
escalate therapy in inflammatory bowel diseases. Aliment Pharmacol 
Ther 2014;40:338–53.
 9 DʼHaens G, Reinisch W, Panaccione R, et al. Lymphoma risk 
and overall safety profile of adalimumab in patients with Crohn's 
disease with up to 6 years of follow- up in the pyramid registry. Am J 
Gastroenterol 2018;113:872–82.
 10 Colombel J- F, Sandborn WJ, Reinisch W, et al. Long- Term safety of 
adalimumab in clinical trials in adult patients with Crohn's disease or 
ulcerative colitis. Aliment Pharmacol Ther 2018;47:219–28.
 11 McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non- 
melanoma skin cancer in inflammatory bowel disease patients 
following tumor necrosis factor-α inhibitor monotherapy and 
in combination with thiopurines: analysis of the food and drug 
administration adverse event reporting system. J Gastrointestin Liver 
Dis 2014;23:267–71.
 12 Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and 
nonmelanoma skin cancer among patients with inflammatory bowel 
disease. Gastroenterology 2012;143:390–9.
Protected by copyright.
 o
n
 June 8, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035326 on 26 May 2020. Downloaded from 
9Smits LJT, et al. BMJ Open 2020;10:e035326. doi:10.1136/bmjopen-2019-035326
Open access
 13 van der Valk ME, Mangen M- JJ, Leenders M, et al. Healthcare costs 
of inflammatory bowel disease have shifted from hospitalisation and 
surgery towards anti- TNFα therapy: results from the coin study. Gut 
2014;63:72–9.
 14 van der Valk ME, Mangen M- JJ, Severs M, et al. Evolution of costs of 
inflammatory bowel disease over two years of follow- up. PLoS One 
2016;11:e0142481.
 15 van den Heuvel TRA, Jeuring SFG, Zeegers MP, et al. A 20- year 
temporal change analysis in incidence, presenting phenotype and 
mortality, in the Dutch IBDSL Cohort- Can diagnostic factors explain 
the increase in IBD incidence? J Crohns Colitis 2017;11:1169–79.
 16 Colombel J- F, Panaccione R, Bossuyt P, et al. Effect of tight control 
management on Crohn's disease (calm): a multicentre, randomised, 
controlled phase 3 trial. Lancet 2018;390:2779–89.
 17 Brodszky V, Rencz F, Péntek M, et al. A budget impact model for 
biosimilar infliximab in Crohn's disease in Bulgaria, the Czech 
Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev 
Pharmacoecon Outcomes Res 2016;16:119–25.
 18 Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory 
bowel disease in Canada 2018: direct costs and health services 
utilization. J Can Assoc Gastroenterol 2019;2:S17–33.
 19 Bots SJA, Hoekman DR, Benninga MA, et al. Patterns of anti- TNF 
use and associated treatment outcomes in inflammatory bowel 
disease patients: results from an analysis of Dutch health insurance 
claims data. Neth J Med 2017;75:S58.
 20 Louis E, Mary J- Y, Vernier- Massouille G, et al. Maintenance of 
remission among patients with Crohn's disease on antimetabolite 
therapy after infliximab therapy is stopped. Gastroenterology 
2012;142:63–70.
 21 van Herwaarden N, van der Maas A, Minten MJM, et al. Disease 
activity guided dose reduction and withdrawal of adalimumab 
or etanercept compared with usual care in rheumatoid arthritis: 
open label, randomised controlled, non- inferiority trial. BMJ 
2015;350:h1389.
 22 Kievit W, van Herwaarden N, van den Hoogen FH, et al. Disease 
activity- guided dose optimisation of adalimumab and etanercept is 
a cost- effective strategy compared with non- tapering tight control 
rheumatoid arthritis care: analyses of the dress study. Ann Rheum 
Dis 2016;75:1939–44.
 23 Papamichael K, Van Stappen T, Jairath V, et al. Review article: 
pharmacological aspects of anti- TNF biosimilars in inflammatory 
bowel diseases. Aliment Pharmacol Ther 2015;42:1158–69.
 24 Tilg H, Moschen A, Kaser A. Mode of function of biological anti- TNF 
agents in the treatment of inflammatory bowel diseases. Expert Opin 
Biol Ther 2007;7:1051–9.
 25 Pouillon L, Lamoureux A, Pineton de Chambrun G, et al. Dose 
de- escalation to adalimumab 40 mg every three weeks in patients 
with inflammatory bowel disease—A multicenter, retrospective, 
observational study. Digestive and Liver Disease 2019;51:236–41.
 26 Van Steenbergen S, Bian S, Vermeire S, et al. Dose de- escalation 
to adalimumab 40 mg every 3 weeks in patients with Crohn's 
disease - a nested case- control study. Aliment Pharmacol Ther 
2017;45:923–32.
 27 Chan A- W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation 
and elaboration: guidance for protocols of clinical trials. BMJ 
2013;346:e7586.
 28 Gomollón F, Dignass A, Annese V, et al. 3Rd European evidence- 
based consensus on the diagnosis and management of Crohn's 
disease 2016: Part 1: diagnosis and medical management. J Crohns 
Colitis 2017;11:3–25.
 29 van Bodegraven AA, van Everdingen JJE, Dijkstra G, et al. [Guideline 
'Diagnosis and treatment of inflammatory bowel disease in adults'. I. 
Diagnosis and treatment]. Ned Tijdschr Geneeskd 2010;154.
 30 Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel 
disease questionnaire: a quality of life instrument for community 
physicians managing inflammatory bowel disease. CCRPT 
Investigators. Canadian Crohn's relapse prevention trial. Am J 
Gastroenterol 1996;91:1571–8.
 31 Khanna R, Zou G, D'Haens G, et al. A retrospective analysis: 
the development of patient reported outcome measures for the 
assessment of Crohn's disease activity. Aliment Pharmacol Ther 
2015;41:77–86.
 32 Janssen MF, Pickard AS, Golicki D, et al. Measurement properties 
of the EQ- 5D- 5L compared to the EQ- 5D- 3L across eight patient 
groups: a multi- country study. Qual Life Res 2013;22:1717–27.
 33 EuroQol Group. EuroQol--a new facility for the measurement of 
health- related quality of life. Health Policy 1990;16:199–208.
 34 Flight L, Julious SA. Practical guide to sample size calculations: non- 
inferiority and equivalence trials. Pharm Stat 2016;15:80–9.
 35 Karmiris K, Paintaud G, Noman M, et al. Influence of Trough serum 
levels and immunogenicity on long- term outcome of adalimumab 
therapy in Crohn's disease. Gastroenterology 2009;137:1628–40.
 36 Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator 
infliximab to biosimilar CT- P13 compared with maintained treatment 
with originator infliximab (NOR- SWITCH): a 52- week, randomised, 
double- blind, non- inferiority trial. Lancet 2017;389:2304–16.
 37 Kahan BC, Morris TP. Reporting and analysis of trials using stratified 
randomisation in leading medical journals: review and reanalysis. 
BMJ 2012;345:e5840.
 38 EMA. Note for guidance on statistical principles for clinical 
trials;CPMP/ICH/363/96. In: E9 statistical principles for clinical trials, 
1998.
 39 Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti- TNF 
discontinuation in inflammatory bowel disease: systematic review 
and meta- analysis. Am J Gastroenterol 2016;111:632–47.
 40 Kennedy NA, Warner B, Johnston E, et al. Anti- Tnf withdrawal in IBD: 
relapse and recapture rates and predictive factors from 160 patients 
in a pan- UK study. J Crohn's Colitis 2015;9:S41–2.
 41 Casanova MJ, Chaparro M, García- Sánchez V, et al. Evolution 
after anti- TNF discontinuation in patients with inflammatory bowel 
disease: a multicenter long- term follow- up study. Am J Gastroenterol 
2017;112:120–31.
 42 Ma C, Battat R, Parker CE, et al. Update on C- reactive protein and 
fecal calprotectin: are they accurate measures of disease activity in 
Crohn's disease? Expert Rev Gastroenterol Hepatol 2019;13:319–30.
 43 D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a 
surrogate marker for endoscopic lesions in inflammatory bowel 
disease. Inflamm Bowel Dis 2012;18:2218–24.
 44 Kennedy NA, Jones G- R, Plevris N, et al. Association between 
level of fecal calprotectin and progression of Crohn's disease. Clin 
Gastroenterol Hepatol 2019;17:2269–76.
 45 Ferreiro- Iglesias R, Barreiro- de Acosta M, Lorenzo- Gonzalez A, et al. 
Accuracy of consecutive fecal calprotectin measurements to predict 
relapse in inflammatory bowel disease patients under maintenance 
with anti- TNF therapy: a prospective longitudinal cohort study. J Clin 
Gastroenterol 2018;52:229–34.
 46 Atalay S, van den Reek JMPA, van Vugt LJ, et al. Tight controlled 
dose reduction of biologics in psoriasis patients with low disease 
activity: a randomized pragmatic non- inferiority trial. BMC Dermatol 
2017;17:6.
Protected by copyright.
 o
n
 June 8, 2020 at Erasm
us M
edical / X51 4300.7802.430.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035326 on 26 May 2020. Downloaded from 
